Comparison of Capecitabine and 5-fluorouracil in Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2013 Jul 5

PMID 23822606

Citations 10

Authors

Yeon-Joo Kim

Woo Jin Lee

Sang Myung Woo

Tae Hyun Kim

Sung-Sik Han

Bo Hyun Kim

Sung Ho Moon

Sang Soo Kim

Young Hwan Koh

Sang-Jae Park

Joo-Young Kim

Dae Yong Kim

Joong-Won Park

Affiliations

Soon will be listed here.

Abstract

Background: Although capecitabine has theoretical advantages in the pharmacokinetics, such as higher intratumoral and lower systemic concentration, relative to bolus 5-fluorouracil (5-FU), outcomes of chemoradiotherapy (CRT) with capecitabine or bolus 5-FU have not been directly compared in patients with locally advanced pancreatic cancer. Therefore, we retrospectively compared the outcomes, including toxicity, tumor response, and overall survival, of oral capecitabine plus radiotherapy (RT) with bolus 5-FU plus RT, in patients with locally advanced pancreatic cancer.

Methods: Between August 2006 and January 2012, 98 patients with locally advanced pancreatic cancer received CRT, with 52 receiving concurrent oral capecitabine and 46 receiving bolus injection of 5-FU. Primary tumor and overall response after CRT were evaluated radiologically, and toxicity, tumor response, and overall survival (OS) were compared in the two groups.

Results: Baseline clinical parameters of the two groups were similar. The rates of ≥ Grade 3 hematologic (0% vs. 8.7%, p = 0.045) and non-hematologic (0% vs. 8.7%, p = 0.045) toxicities were significantly lower in the capecitabine group than in the 5-FU group. Primary tumor (30.7% vs. 28.2%, p = 0.658) and overall (13.7% vs. 15.2%, p = 0.273) response rates and median OS time (12.5 months vs. 11.6 months, p = 0.655) were similar in the two groups.

Conclusions: Capecitabine plus RT may be a safe and feasible regimen for patients with locally advanced pancreatic cancer, with similar efficacy and low rates of toxicities compared with bolus 5-FU plus RT.

Citing Articles

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer.

Jie C, Li R, Cheng Y, Wang Z, Wu Q, Xie C Front Immunol. 2023; 14:1122352.

PMID: 36875059 PMC: 9981667. DOI: 10.3389/fimmu.2023.1122352.

A phantom-based analysis for tracking intra-fraction pancreatic tumor motion by ultrasound imaging during radiation therapy.

Ji T, Feng Z, Sun E, Ng S, Su L, Zhang Y Front Oncol. 2022; 12:996537.

PMID: 36237341 PMC: 9552199. DOI: 10.3389/fonc.2022.996537.

The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy.

Zhu X, Wang Y, Tan L, Fu X Cancer Med. 2018; 7(8):3812-3819.

PMID: 29952116 PMC: 6089158. DOI: 10.1002/cam4.1614.

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma.

Wysocka O, Kulbacka J, Saczko J Prz Gastroenterol. 2016; 11(3):155-162.

PMID: 27713776 PMC: 5047971. DOI: 10.5114/pg.2016.61438.

Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.

Chan E, Arlinghaus L, Cardin D, Goff L, Berlin J, Parikh A Radiother Oncol. 2016; 119(2):312-8.

PMID: 27106554 PMC: 4961249. DOI: 10.1016/j.radonc.2016.04.013.

References

Hofheinz R, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann J . Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012; 13(6):579-88. DOI: 10.1016/S1470-2045(12)70116-X. View

Huguet F, Girard N, Guerche C, Hennequin C, Mornex F, Azria D . Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009; 27(13):2269-77. DOI: 10.1200/JCO.2008.19.7921. View

Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L . Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2001; 45(4):291-7. DOI: 10.1007/s002800050043. View

Crane C, Abbruzzese J, Evans D, Wolff R, Ballo M, Delclos M . Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys. 2002; 52(5):1293-302. DOI: 10.1016/s0360-3016(01)02740-7. View

Kim T, Han S, Park S, Lee W, Woo S, Yoo T . CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010; 81(5):e743-8. DOI: 10.1016/j.ijrobp.2010.10.011. View

Ben-Josef E, Shields A, Vaishampayan U, Vaitkevicius V, El-Rayes B, McDermott P . Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 59(2):454-9. DOI: 10.1016/j.ijrobp.2003.11.019. View

. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988; 80(10):751-5. View

Mukherjee S, Hurt C, Bridgewater J, Falk S, Cummins S, Wasan H . Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013; 14(4):317-26. PMC: 3620899. DOI: 10.1016/S1470-2045(13)70021-4. View

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View

10.

Ajani J, Faust J, Ikeda K, Yao J, Anbe H, Carr K . Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005; 23(28):6957-65. DOI: 10.1200/JCO.2005.01.917. View

11.

Ohtsu A, Yoshida S, Saijo N . Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006; 24(14):2188-96. DOI: 10.1200/JCO.2006.05.9758. View

12.

Yoo T, Lee W, Woo S, Kim T, Han S, Park S . Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 81(4):e623-30. DOI: 10.1016/j.ijrobp.2011.02.063. View

13.

MOERTEL C, Frytak S, Hahn R, Oconnell M, Reitemeier R, Rubin J . Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study.... Cancer. 1981; 48(8):1705-10. DOI: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4. View

14.

Kim J, Lim J, Kim J, Im S, Chie E, Hwang J . Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2012; 70(3):381-9. DOI: 10.1007/s00280-012-1918-7. View

15.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K . Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34(8):1274-81. DOI: 10.1016/s0959-8049(98)00058-6. View

16.

Roche C, Hughes M, Garvey C, Campbell F, White D, Jones L . CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol. 2003; 180(2):475-80. DOI: 10.2214/ajr.180.2.1800475. View

17.

Oconnell M, Martenson J, Wieand H, Krook J, Macdonald J, Haller D . Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331(8):502-7. DOI: 10.1056/NEJM199408253310803. View

18.

Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H . X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999; 5(10):2948-53. View

19.

. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg. 1979; 189(2):205-8. PMC: 1397020. View

20.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View